Dr Gisela Mautner


MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia), AMCEOI, MAICD

Dr Mautner is an international business leader with significant experience developing and launching new pharmaceutical products, and delivering successful corporate strategies in highly competitive global markets.

After joining Noxopharm in 2019 as Chief Medical Officer, Gisela was appointed to the CEO and Managing Director roles in early 2022. Her focus is on leading the strategy for Noxopharm’s next stage of development, and the creation and out-licensing of drug assets in oncology and inflammatory disease.

In addition to serving on the Noxopharm Board, she is also a Non-Executive Director of Nyrada Inc, a US biotechnology company listed on the ASX, as well as a member of the Board of NFP Australian Ice Racing.

Before joining Noxopharm, Gisela spent more than 30 years in the medical sector, including leadership in global pharmaceutical organisations across multiple continents and therapeutic areas.

Having held senior positions at major companies including MSD (Merck), Bayer and Amgen, in roles encompassing operations, medical and scientific advisory, research and marketing, Gisela brings a deep understanding of the industry to Noxopharm.

Gisela has strong industry networks and served as President, Vice-President and Treasurer of the Australian Pharmaceutical Physicians Association (APPA) for many years, and is currently serving as Past-President. She is also the Australian delegate for the International Federation of Associations of Pharmaceutical Physicians (IFAPP), which connects the pharmaceutical industry globally.

Gisela’s leadership experience is founded on an education at some of the world’s highest-ranking institutions, with an MBA from the Kellogg School of Management at Northwestern University in Chicago, a Master of Public Health from Harvard, a PhD from Ludwig Maximilian University in Munich, and a Doctor of Medicine degree from Technical University in Munich. She is also a Member of the Australian Institute of Company Directors and the CEO Institute.